Editas Medicine, Inc. (NASDAQ:EDIT) Given "Hold" Rating at Cann

Cesar Mills
August 13, 2017

For the current year the company's revenue estimates are $476.39 Million compared to low analyst estimates of $456.39 Million and high estimates of $517 Million according to the prediction of 15 analysts.

In the last earnings report the EPS was $-3.09 and is estimated to be $-3.04 for the current year with 40,729,000 shares presently outstanding. Schwab Charles Investment Management Inc. now owns 42,150 shares of the company's stock worth $941,000 after buying an additional 3,249 shares in the last quarter. A negative earnings surprise will usually result in a decline in share price.

Looking at insider trading can give great insight into how Editas Medicine, Inc. For the same quarter last year, the business reported ($0.54) EPS. on consensus, Brokerage firms anticipate that Editas Medicine to post ($2.84) EPS for the full year. Editas Medicine had a negative net margin of 1,864.00% and a negative return on equity of 63.29%. The firm's revenue for the quarter was down 8.8% compared to the same quarter a year ago.

Several other equities analysts have also issued reports on EDIT. Zacks Investment Research lowered Editas Medicine from a "buy" rating to a "hold" rating in a research report on Tuesday, July 18th. Oppenheimer Holdings, Inc. reiterated a "market perform" rating on shares of Editas Medicine in a research note on Tuesday, July 18th. Cann reaffirmed a "hold" rating on shares of Editas Medicine in a research report on Thursday. Finally, SunTrust Banks, Inc. assumed coverage on Editas Medicine in a research note on Thursday, July 13th.

Editas Medicine Inc has an analyst consensus of Hold, with a price target consensus of $27. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal. Editas Medicine has a consensus rating of "Buy" and a consensus target price of $25.03.

Rogue elephant tramples 15 to death in India, faces culling
The marauding elephant likely wandered from its herd and became lost, straying into villages where the killings took place. Overnight the elephant was travelling as far as 20 kilometers and was destroying homes of people and injuring them.

Venezuela calls Trump's warning of possible military action a 'crazy act'
The president did not answer a question about whether American troops would lead a potential operation. The White House said late Friday that Maduro requested a phone call with Trump.

Dow slips 100 points as tensions with North Korea escalate
The Nasdaq finished the day at 6,216.87, a slide of 135.46, while the S&P 500 lost almost 1.5 percent, ending the day at 2,438.21. The pan-European benchmark on Wednesday fell 0.7% in a sell-off prompted by tensions between the USA and North Korea escalated.

ILLEGAL ACTIVITY WARNING: "Zacks: Analysts Expect Editas Medicine, Inc. (NASDAQ:EDIT) Expected to Announce Quarterly Sales of $2.88 Million" was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are viewing this piece on another website, it was stolen and reposted in violation of United States and global copyright legislation. The company had revenue of $3.10 million during the quarter, compared to analyst estimates of $2.20 million. Gerald Frank Cox, Chief Medical Officer disclosed the purchase of 4,000 shares. Director Boris Nikolic purchased 35,000 shares at an average price of $14.07 on Friday the 2nd. The Director now owns $47,551,448 of the stock per the Form 4 SEC filing.

Kevin Bitterman, Director reported the sale of 1,000,000 shares of EDIT stock. With 806,900 shares average volume, it will take short sellers 8 days to cover their EDIT's short positions. The disclosure for this bought can be found here.

The following firms have also recently changed their position in EDIT. Bank of New York Mellon Corp now owns 142,122 shares of the company's stock valued at $2,385,000 after buying an additional 78,632 shares during the period. This gauge is crucial in determining whether investors are moved toward the direction of buying more of the stock, or else doing the contradictory side and selling more of the stock. Driehaus Capital Management has an ownership of 125,684 stocks of the firms shares valued $2,805,000 after scooping up an extra 79,104 shares through out the quarter. large institution funds own 67.87% of the firms stock. Russell Investments Group bought a fresh position in stocks of Editas Medicine throughout the Q4 valued about $284,000.

About 1.13 million shares traded or 71.40% up from the average. Finally, Goldman Sachs Group Inc. boosted its position in shares of Editas Medicine by 16.7% in the first quarter. Creative Planning now owns 9,101 shares of the company's stock valued at $153,000 after buying an additional 9,000 shares during the last quarter.

Editas Medicine (NASDAQ EDIT) opened at 17.14 on Friday. The stock was trading on above-average volume. Editas Medicine has a 52 week low of $12.43 and a 52 week high of $29.20. The stock's market valuation is $898.04 M. Company's 50 Day SMA price is $17.07 and its 200 SMA price is $18.99. Editas Medicine, Inc. The firm has a 50-day moving average price of $17.20 and a 200-day moving average price of $19.02.

Other reports by GizPress

Discuss This Article